Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:
Nathan Pennell, MD, PhD
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
The Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Safety and response data from phase Ib TROPION-Lung02 study of Dato-DXd plus pembrolizumab with or without platinum chemotherapy in advanced NSCLC, presented at WCLC 2022 reported by Clinical Care Options (CCO)
Results from the HUDSON umbrella trial of novel durvalumab combination regimens in patients with advanced NSCLC who failed previous immunotherapy treatment, presented at WCLC 2022 and reported by Clinical Care Options (CCO)
Initial PFS and OS results from phase II NADIM II study of neoadjuvant nivolumab plus CT vs CT alone in patients with resectable stage IIIA-B NSCLC, presented at WCLC 2022 and reported by Clinical Care Options (CCO)
Evaluation of YESS study adding personalized smoking cessation support to a lung cancer screening program, presented at WCLC 2022 and reported by Clinical Care Options (CCO)